Calidi Biotherapeutics (CLDI) Total Liabilities (2021 - 2025)

Calidi Biotherapeutics has reported Total Liabilities for 5 years, with the latest figure at $5.1 million in Q4 2025.

• For the quarter ending Q4 2025, Total Liabilities fell 58.26% year-over-year to $5.1 million; the trailing twelve-month figure through Dec 2025 stood at $5.1 million (down 58.26% YoY), and the FY2025 full-year result was $5.1 million, down 58.26% from the prior year.
• Total Liabilities for Q4 2025 stood at $5.1 million, down from $6.8 million in the prior quarter.
• The five-year high for Total Liabilities was $43.4 million in Q4 2022, with the low at $5.1 million in Q4 2025.
• Average Total Liabilities over 5 years is $14.7 million, with a median of $12.8 million recorded in 2023.
• Year-over-year, Total Liabilities surged 169.58% in 2024 and tumbled 64.67% in 2025.
• Tracing CLDI's Total Liabilities over 5 years: stood at $16.5 million in 2021, then jumped by 164.03% to $43.4 million in 2022, then sank by 57.97% to $18.3 million in 2023, then tumbled by 33.09% to $12.2 million in 2024, then plunged by 58.26% to $5.1 million in 2025.
• The last three Total Liabilities figures came in at $5.1 million (Q4 2025), $6.8 million (Q3 2025), and $7.3 million (Q2 2025), per Business Quant data.

Peer Comparison